Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Change in Accured Expenses (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Change in Accured Expenses over the past 3 years, most recently at $10.1 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $10.1 million for Q4 2025, up 551.29% from a year ago — trailing twelve months through Dec 2025 was $11.7 million (up 886.97% YoY), and the annual figure for FY2025 was $11.7 million, up 886.97%.
  • Change in Accured Expenses for Q4 2025 was $10.1 million at Tonix Pharmaceuticals Holding, up from $1.2 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for TNXP hit a ceiling of $10.1 million in Q4 2025 and a floor of -$3.0 million in Q1 2023.
  • Median Change in Accured Expenses over the past 3 years was $1.1 million (2024), compared with a mean of $1.2 million.
  • Peak annual rise in Change in Accured Expenses hit 551.29% in 2025, while the deepest fall reached 68.96% in 2025.
  • Tonix Pharmaceuticals Holding's Change in Accured Expenses stood at $4.4 million in 2023, then tumbled by 65.02% to $1.5 million in 2024, then soared by 551.29% to $10.1 million in 2025.
  • The last three reported values for Change in Accured Expenses were $10.1 million (Q4 2025), $1.2 million (Q3 2025), and $3.4 million (Q2 2025) per Business Quant data.